Cardiol Therapeutics Inc. (CRDL) Stock

Cardiol Therapeutics Inc. (CRDL) is a Healthcare stock trading at $1.06 (as of 2026-06-18), with a market capitalization of $122.31M and a trailing P/E of -2.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cardiol Therapeutics Inc. is a clinical-stage life sciences company developing therapies targeting fibrosis and inflammation for cardiovascular disease, including CardiolRx. It is testing CardiolRx in Phase II/III randomized, double-blind, placebo-controlled studies and is also developing a subcutaneous formulation aimed at treating cardiac fibrosis and inflammation.

Valuation — source: SEC EDGAR (first-party)
Price$1.06
Market Cap$122.31M
P/E Ratio-2.6
Price / Book5.78
DCF Value (model)$-3.84
DCF Upside vs Price-460.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$78760.00
Net Margin-40170.4%
Return on Equity-189.2%
Current Ratio4.16
Valuation vs Sector & Industry
Stock P/E-2.6
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-112.6%
vs Industry-115.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMMCAP International Inc. SPC ($20.73M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODavid G. Elsley
Employees18
CountryCA
IPO Date2019-01-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Champions Oncology, Inc. (CSBR)
  • Precision BioSciences, Inc. (DTIL)
  • Sutro Biopharma, Inc. (STRO)
  • Pelthos Therapeutics Inc. (PTHS)
  • Cypherpunk Technologies Inc. (CYPH)
  • Oncolytics Biotech Inc. (ONCY)
  • Equillium, Inc. (EQ)
  • Annovis Bio, Inc. (ANVS)
CRDL earnings history · CRDL institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.